Verquvo®

Active substance Vericiguat
Holder Bayer
Status Running
Indication Adult patients with symptomatic chronic heart failure (New York Heart Association (NYHA) Class II-III-IV) with a reduced ejection fraction who are stabilized after a previous decompensation event requiring IV therapy.
Public documents Approbation
  Information for the patient
  Informed consent
Lastupdate 10/08/2022

 

Last updated on 28/09/2022